Population-based validation of the prognostic model ADJUVANT! for early breast cancer - PubMed (original) (raw)
. 2005 Apr 20;23(12):2716-25.
doi: 10.1200/JCO.2005.06.178.
Affiliations
- PMID: 15837986
- DOI: 10.1200/JCO.2005.06.178
Population-based validation of the prognostic model ADJUVANT! for early breast cancer
Ivo A Olivotto et al. J Clin Oncol. 2005.
Abstract
Purpose: Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated.
Methods: Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer-specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared.
Results: Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted-observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted-observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different.
Conclusion: Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.
Similar articles
- Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies.
Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Chia SK, et al. J Clin Oncol. 2004 May 1;22(9):1630-7. doi: 10.1200/JCO.2004.09.070. J Clin Oncol. 2004. PMID: 15117985 - Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy.
Dinshaw KA, Budrukkar AN, Chinoy RF, Sarin R, Badwe R, Hawaldar R, Shrivastava SK. Dinshaw KA, et al. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1132-41. doi: 10.1016/j.ijrobp.2005.03.071. Epub 2005 Jun 22. Int J Radiat Oncol Biol Phys. 2005. PMID: 15978744 - Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
Truong PT, Yong CM, Abnousi F, Lee J, Kader HA, Hayashi A, Olivotto IA. Truong PT, et al. J Am Coll Surg. 2005 Jun;200(6):912-21. doi: 10.1016/j.jamcollsurg.2005.02.010. J Am Coll Surg. 2005. PMID: 15922205 - Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Ozanne EM, et al. J Clin Oncol. 2009 Jan 10;27(2):214-9. doi: 10.1200/JCO.2008.17.3914. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047286 - Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Hanrahan EO, et al. J Clin Oncol. 2006 May 1;24(13):2113-22. doi: 10.1200/JCO.2005.02.8035. J Clin Oncol. 2006. PMID: 16648513 Review.
Cited by
- Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study.
Esin E, Yildirim HC, Oksuzoglu B, Markoc F, Guntekin S, Bilgetekin I, Yildiz F, Yukruk F, Demirci U, Cetin-Atalay R. Esin E, et al. J Clin Med. 2024 Sep 9;13(17):5328. doi: 10.3390/jcm13175328. J Clin Med. 2024. PMID: 39274541 Free PMC article. - The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer.
Bar Y, Bar K, Feldman D, Dror JB, Shahoha M, Lerner S, Shachar SS, Weiss-Meilik A, Dershowitz N, Wolf I, Sonnenblick A. Bar Y, et al. Breast. 2024 Oct;77:103777. doi: 10.1016/j.breast.2024.103777. Epub 2024 Jul 14. Breast. 2024. PMID: 39038425 Free PMC article. - Breast cancer gene expression signatures: development and clinical significance-a narrative review.
Li S, Yu X, Xu Y. Li S, et al. Transl Breast Cancer Res. 2022 Oct 27;4:7. doi: 10.21037/tbcr-22-39. eCollection 2023. Transl Breast Cancer Res. 2022. PMID: 38751471 Free PMC article. Review. - A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer.
Magno E, Bussard KM. Magno E, et al. Int J Mol Sci. 2024 Mar 17;25(6):3407. doi: 10.3390/ijms25063407. Int J Mol Sci. 2024. PMID: 38542380 Free PMC article. Review. - Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland.
McSorley LM, Tharmabala M, Al Rahbi F, Keane F, Evoy D, Geraghty JG, Rothwell J, McCartan DP, Greally M, O'Connor M, O'Mahony D, Keane M, Kennedy MJ, O'Reilly S, Millen SJ, Crown JP, Kelly CM, Prichard RS, Quinn CM, Walshe JM. McSorley LM, et al. Curr Oncol. 2024 Mar 1;31(3):1302-1310. doi: 10.3390/curroncol31030098. Curr Oncol. 2024. PMID: 38534931 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical